Small Extracellular Vesicle‐Derived Nidogen 1 Promotes HCC Carcinogenesis via Transglutaminase 3‐Mediated YAP/TAZ Signalling
Journal of Extracellular Vesicles · 2026
DOI: 10.1002/jev2.70359 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Extracellular Vesicles, 2026. Verfasst von Cherlie Lot Sum Yeung und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, China. Hauptthemen laut MEDLINE: Liver Neoplasms, Carcinoma, Hepatocellular, Transglutaminases, Extracellular Vesicles. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Research Grants Council General Research Fund, Research Grants Council Theme-Based Research Scheme, Innovation and Technology Commission Innovative and Technology Support Programme Seed Projects.
Abstract (Originalsprache)
Tumour‐derived small extracellular vesicles (sEV) are increasingly recognized as key mediators of cancer progression and metastasis by facilitating intercellular communication. In this study, we identify nidogen 1 (NID1), a basement membrane glycoprotein, as significantly enriched in sEV from metastatic hepatocellular carcinoma (HCC) cells. We demonstrate that the sEV‐mediated delivery of NID1 enhances oncogenic behaviours, including proliferation, invasion and metastasis. Knockout mice of NID1 exhibited a marked delay in liver tumour formation induced by N‐diethylnitrosamine (DEN) and carbon tetrachloride (CCL4), or hydrodynamic injection delivery of oncogenes, underscoring the role of NID1 in hepatocarcinogenesis. Importantly, we find that a stiffer extracellular matrix, a characteristic of tumour microenvironments, stimulates increased NID1 level in sEV. Using NID1 mutants, we identify the C‐terminal domain as critical for its oncogenic functions, including promoting tumour growth and metastasis. Proteomic profiling reveals that transglutaminase 3 (TGM3) interacts with NID1 via its C‐terminus. Subsequent analyses indicate that sEV‐NID1 elevates TGM3 levels, leading to dysregulation of integrins and activation of the YAP/TAZ signalling pathway, thereby contributing to tumour progression. To explore therapeutic potential, we developed a novel monoclonal anti‐NID1 antibody (anti‐NID1 mAb) and evaluated its efficacy in multiple HCC mouse models. The antibody markedly suppressed liver tumour growth and metastasis of human and murine HCC cells. The therapeutic effect was further enhanced when combined with sorafenib, a standard treatment for HCC. Our findings delineate a novel sEV‐NID1‐TGM3 regulatory axis that promotes hepatocarcinogenesis and metastasis and suggest that targeting sEV‐delivered NID1 with our homemade monoclonal antibody offers a promising avenue for therapeutic intervention in HCC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pathology, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, China.
- State Key Laboratory of Mechanism and Quality of Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Macao, China.
- Department of Surgery, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, China.
- School of Biomedical Sciences, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, China.
- State Key Laboratory of Liver Research, The University of Hong Kong, Hong Kong, China.
- Materials Innovation Institute for Life Sciences and Energy (MILES), The University of Hong Kong Shenzhen Institute of Research and Innovation (HKU-SIRI), Shenzhen, China.
ORCID-Profile: Judy Wai Ping Yam
Förderung
- Research Grants Council General Research Fund
- Research Grants Council Theme-Based Research Scheme
- Innovation and Technology Commission Innovative and Technology Support Programme Seed Projects
- University Research Committee Seed Fund for Basic Research
- University Research Committee Seed Fund for Translational and Applied Research
- State Key Laboratory of Liver Research (The University of Hong Kong) Young Researcher Support Scheme
- Laboratory for Synthetic Chemistry and Chemical Biology" under the Health@InnoHK Program launched by Innovation and Technology Commission, the Government of Ho…
Zitieren
APA
Yeung, C. L. S., Cui, L., Wang, J., Chan, C. P., Ng, T. H., Lai, C. J., Mao, X., Tey, S. K., Huen, M. S. Y., & Yam, J. W. P. (2026). Small Extracellular Vesicle‐Derived Nidogen 1 Promotes HCC Carcinogenesis via Transglutaminase 3‐Mediated YAP/TAZ Signalling. Journal of Extracellular Vesicles. https://doi.org/10.1002/jev2.70359
Vancouver
Yeung CLS, Cui L, Wang J, Chan CP, Ng TH, Lai CJ, et al. Small Extracellular Vesicle‐Derived Nidogen 1 Promotes HCC Carcinogenesis via Transglutaminase 3‐Mediated YAP/TAZ Signalling. Journal of Extracellular Vesicles. 2026. doi:10.1002/jev2.70359
BibTeX
@article{Yeung2026,
author = {Yeung, Cherlie Lot Sum and Cui, Le and Wang, Jingyi and Chan, Ching-Ping and Ng, Tung Him and Lai, Charlotte Jiaqi and Mao, Xiaowen and Tey, Sze Keong and Huen, Michael Shing Yan and Yam, Judy Wai Ping},
title = {Small Extracellular Vesicle‐Derived Nidogen 1 Promotes HCC Carcinogenesis via Transglutaminase 3‐Mediated YAP/TAZ Signalling},
journal = {Journal of Extracellular Vesicles},
year = {2026},
doi = {10.1002/jev2.70359}
}
EUVIMED